# OnCo record capmatinib-tepotinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/capmatinib-tepotinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "capmatinib-tepotinib" ;
  schema:name "Capmatinib & tepotinib"@en ;
  schema:description "Capmatinib and tepotinib are two pills for the roughly 3% of lung cancers with a MET exon 14 skipping mutation."@en ;
  schema:url <https://onco.cc/drugs/capmatinib-tepotinib/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Capmatinib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q27075685> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Capmatinib%20%26%20tepotinib> ;
  onco:status "approved" ;
  onco:modality "Small-molecule kinase inhibitors (MET)" ;
  schema:alternateName "Tabrecta / Tepmetko" ;
  onco:approval "US 2020: MET exon 14 skipping NSCLC (capmatinib; tepotinib 2021)", "EU 2022: Tepmetko 2022; Tabrecta 2022" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/met-altered-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/met/> ;
  onco:companies <https://onco.cc/companies/novartis/>, <https://onco.cc/companies/merck/> ;
  onco:trials <https://onco.cc/trials/geometry-mono-1/>, <https://onco.cc/trials/nct02864992/> .